ABSTRACT:
Tafamidis, available under the brand names Vyndaqel and Vyndamax, is a medication used to help slow the progression of transthyretin amyloidosis in adults. This rare condition can be inherited, as seen in familial amyloid cardiomyopathy and familial amyloid polyneuropathy, or it can occur without a genetic link, such as in wild-type transthyretin amyloidosis (previously called senile systemic amyloidosis). The drug works by binding to the transthyretin protein and stabilizing its structure, which helps prevent it from breaking apart and forming amyloid deposits that can harm organs like the heart and nervous system. Tafamidis has been recognized by the U.S. Food and Drug Administration as a first-in-class therapy due to its novel mechanism of action.
Cite this article:
Mayur S. Jain, Shashikant D. Barhate. A Review on Tafamidis to Treat a Genetic condition that affects Nerves and may lead to High Blood Pressure and Other Heart Problems. Asian Journal of Pharmaceutical Research. 2026; 16(1):83-6. doi: 10.52711/2231-5691.2026.00010
Cite(Electronic):
Mayur S. Jain, Shashikant D. Barhate. A Review on Tafamidis to Treat a Genetic condition that affects Nerves and may lead to High Blood Pressure and Other Heart Problems. Asian Journal of Pharmaceutical Research. 2026; 16(1):83-6. doi: 10.52711/2231-5691.2026.00010 Available on: https://asianjpr.com/AbstractView.aspx?PID=2026-16-1-10
REFERENCES:
1. Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Plante-Bordeneuve V, Labaudiniere R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun; 5(1): 1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. [Article]
2. Gurwitz JH, Maurer MS. Tafamidis-A Pricey Therapy for a Not-So-Rare Condition. JAMA Cardiol. 2020 Jan 8. pii: 2758314. doi: 10.1001/jamacardio.2019.5233. [Article]
3. Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis. Circ J. 2019 Dec 25; 84(1):15-17. doi: 10.1253/circj.CJ-19-0811. Epub 2019 Nov 16. [Article]
4. Ratner M. Spotlight focuses on protein-misfolding therapies. Nat Biotechnol. 2009 Oct; 27(10): 874. doi: 10.1038/nbt1009-874c.
5. Lee KR, Jeong JW, Hyun HC, Jang E, Ahn S, Choi S, Joo SH, Kim S, Koo TS. Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats. Xenobiotica. 2018 Aug; 48(8):831-838. doi: 10.1080/00498254.2017.1366575. Epub 2017 Nov 16.
6. Tafamadis SmPC EMA
7. FDA Approved Drug Products: Vyndaqel Tafamidis Meglumine Oral Capsules